The insulin in dosage market size value per capita in Poland is showing a declining trend from 2024 to 2028. The actual value in 2023 stood at approximately 8.20 USD per capita. From 2024 onwards, the forecasted values show a steady decrease year-on-year:
● 2024: 7.89 USD per capita (-3.78% YoY)
● 2025: 7.57 USD per capita (-4.06% YoY)
● 2026: 7.25 USD per capita (-4.23% YoY)
● 2027: 6.95 USD per capita (-4.14% YoY)
● 2028: 6.64 USD per capita (-4.46% YoY)
Over the last five years from 2023 to 2028, the Compound Annual Growth Rate (CAGR) is estimated to be -4.14%, highlighting a consistent annual decline in per capita expenditure on insulin dosage.
Future trends to watch for include advancements in insulin delivery technology, policy changes affecting healthcare funding, and the potential impact of new diabetes management drugs entering the market. Monitoring these factors could provide insights into any shifts in insulin demand and market dynamics.
